Resumo não disponível

Resumo não disponível

This work focuses on anorexigenic neuropeptides, cocaine- and amphetamine-regulated transcript (CART) and prolactin-releasing peptide (PrRP), which decrease food intake and body weight. CART peptide is an anorexigenic neuropeptide and, despite many efforts, its receptor has not yet been identified. We found CART peptide specific binding sites in pheochromocytoma PC12 cells. Cells differentiated to neurons increased significantly the number of binding sites. On the other hand, after differentiation to chromaffin cells the number of binding sites was so low that it was impossible to determine their density. To clarify the importance of each of the three disulfide bridges in the CART molecule, analogs with one or two disulfide bridges were synthetized. The biological activity was maintained in analog with two disulfide bridges in positions 74-94 and 88-101. Moreover, we demonstrated the stimulation of JNK and subsequently c-Jun activation in PC12 cells. Neuropeptide PrRP belongs to the RF-amide peptide family and has anorexigenic properties. PrPR has a high affinity to GPR10 and neuropeptide FF (NPFF2) receptor. In our laboratory lipidized analogs of PrRP were synthesized, which are able to decrease food intake after peripheral administration and may cross the blood-brain barrier. We tested biological...

Einleitung: Die Mucositis enoralis stellt die bedeutendste und schwerwiegendste frühe Nebenwirkung bei der Strahlentherapie fortgeschrittener Kopf-Hals-Tumoren dar. Sie führt häufig zu einer Unterbrechung der Behandlung, mit der Folge einer reduzierten Tumorheilungschance. Des Weiteren wirkt sie sich nachteilig auf die Lebensqualität aus, erhöht das Risiko später Nebenwirkungen und Infektionen und stellt einen erheblichen Kostenfaktor dar. Trotz umfangreicher experimenteller und klinischer Untersuchungen wurde bisher keine allgemein anerkannte Strategie zur Prophylaxe oder Therapie der Mucositis enoralis klinisch etabliert. Die Blockade der Cyclooxygenase-2 (COX-2), welche in einer Reihe von Tumoren überexprimiert wird, wird in der Kombination mit einer Strahlentherapie diskutiert. Außerdem kommen COX-2-Inhibitoren als entzündungshemmende Medikamente therapiebegleitend zum Einsatz. C-Jun und NF-kB p50 sind Transkriptionsfaktoren, die möglicherweise in der Pathogenese der radiogenen Mukositis eine wichtige Rolle spielen. Ziel der Untersuchungen: Ziel der vorliegenden Arbeit ist es, die Wirkung von Celecoxib, einem selektiven COX-2-Inhibitor, auf die Strahlenreaktion der oralen Mukosa (Zellzahl, Epitheldicke) und die epitheliale Expression von c-Jun und NF-kB p50 im etablierten Tiermodell der Schleimhaut der Zungenunterseite der Maus zu untersuchen. So soll festgestellt werden, ob eine Interaktion zwischen den begleitenden Entzündungsreaktionen und der eigentlichen epithelialen Strahlenreaktion besteht. Material und Methoden: In vorangegangenen Untersuchungen wurden die Schnauzen von Mäusen des Stammes C3H/Neu mit 5x3 Gy/Woche über 2 Wochen (Tag 0-4, 7-14) bestrahlt (200 kV Röntgenstrahlung). In einer weiteren Versuchsgruppe erhielten die Tiere täglich an den Tagen 0 bis 13 25 mg/kg/Tag Celecoxib oral per Schlundsonde. Im vierzehntägigen Untersuchungszeitraum wurden täglich jeweils 5 Mäuse je Versuchsgruppe getötet, deren Zungen entnommen und fixiert. In diesem Zustand wurde das Material von der Autorin dieser Arbeit übernommen. Mit Hilfe eines Zählrasters wurden in den vorliegenden Untersuchungen die Zellzahl, die Epitheldicke und die Expression von c-Jun und NF-kB p50 im Epithel der Zungenunterseite der unbehandelten Kontrolle (n = 5), während alleiniger Bestrahlung, sowie nach Bestrahlung und Gabe von Celecoxib manuell erfasst. Aufgrund der geringen Tierzahlen pro Untersuchungszeitpunkt (n = 5) und Versuchsgruppe wurde auf eingehende statistische Analysen verzichtet. Die vorliegende Arbeit beschränkt sich auf eine beschreibende Darstellung des Verlaufs der Einzelparameter über den Gesamtzeitraum. Ergebnisse: Das unbehandelte Epithel besteht aus 402 ± 11 Zellen, wobei 281 ± 8 Zellen der Germinativ- und 121 ± 4 Zellen der funktionellen Schicht angehören. Die Dicke des Gesamtepithels beträgt 68 ± 3 μm. Davon nehmen Germinativ- und Keratinschicht je 15 ± 1 μm und die funktionelle Schicht 38 ± 4 μm ein. Im Kontrollepithel wird c-Jun von 81 % der Zellen der funktionellen und von 80 % der Zellen der Germinativschicht exprimiert, wobei die funktionelle Schicht scheinbar eine größere Färbeintensität aufweist. NF-kB p50 wird von 79 % der Epithelzellen exprimiert, wobei eine stärkere Expression in der Germinativschicht zu beobachten ist. Bei alleiniger fraktionierter Bestrahlung verringert sich die Zellzahl innerhalb der ersten Woche auf 68 % des Kontrollwertes und bleibt anschließend trotz weiterer Bestrahlung weitestgehend konstant. Der größere Anteil an Zellen geht dabei in der funktionellen Schicht verloren. Die Epitheldicke nimmt in der ersten Bestrahlungswoche bis auf 113 % zu und liegt in der folgenden Woche im normalen bis subnormalen Bereich. Die epitheliale c-Jun-Expression nimmt unmittelbar nach Bestrahlungsbeginn zu und liegt anschließend während des gesamten Beobachtungszeitraums über dem Kontrollbereich. Während der gesamten Bestrahlung liegt die Färbeintensität der funktionellen Schicht weiterhin über derer der Germinativschicht. Auch bei NF-kB p50 nimmt die Färbeintensität in der ersten Bestrahlungswoche zu und bleibt anschließend erhöht. Der Anteil NF-kB p50 exprimierender Zellen ist in der Germinativschicht scheinbar größer als in der funktionellen Schicht. Unter zusätzlicher Celecoxibgabe liegen die Zellzahlen vom 6.-12. Tag des Beobachtungszeitraums vermutlich unterhalb derjenigen bei alleiniger Bestrahlung. Dieser Effekt ist besonders innerhalb der Germinativschicht sichtbar. Der Anstieg der Epitheldicke in der ersten Bestrahlungswoche fällt bei zusätzlicher Celecoxibtherapie stärker aus. Im weiteren Verlauf sind kaum Differenzen zu verzeichnen. Die epitheliale Färbeintensität von c-Jun unterscheidet sich kaum von den alleinig bestrahlten Tieren. Bei NF-kB p50 ist dies mit Ausnahme einer scheinbar geringeren Expressionsintensität am 8. und 13. Beobachtungstag ebenso. Schlussfolgerungen: Bei der frühen Strahlenreaktion der Mundschleimhaut werden c-Jun und NF-kB p50 verändert exprimiert. Celecoxib reduziert im Vergleich zur alleinigen Bestrahlung die Zellzahl und verstärkt die Zunahme der Epitheldicke. Es hat keinen Einfluss auf die Expression von c-Jun und NF-kB p50. Somit ist die Regulation der Aktivität von c-Jun und NF-kB p50 unabhängig von der Aktivität von COX-2 erfolgt.

This work focuses on anorexigenic neuropeptides, cocaine- and amphetamine-regulated transcript (CART) and prolactin-releasing peptide (PrRP), which decrease food intake and body weight. CART peptide is an anorexigenic neuropeptide and, despite many efforts, its receptor has not yet been identified. We found CART peptide specific binding sites in pheochromocytoma PC12 cells. Cells differentiated to neurons increased significantly the number of binding sites. On the other hand, after differentiation to chromaffin cells the number of binding sites was so low that it was impossible to determine their density. To clarify the importance of each of the three disulfide bridges in the CART molecule, analogs with one or two disulfide bridges were synthetized. The biological activity was maintained in analog with two disulfide bridges in positions 74-94 and 88-101. Moreover, we demonstrated the stimulation of JNK and subsequently c-Jun activation in PC12 cells. Neuropeptide PrRP belongs to the RF-amide peptide family and has anorexigenic properties. PrPR has a high affinity to GPR10 and neuropeptide FF (NPFF2) receptor. In our laboratory lipidized analogs of PrRP were synthesized, which are able to decrease food intake after peripheral administration and may cross the blood-brain barrier. We tested biological...

Hepatitis C virus (HCV) induces a high rate of chronic infection via dysregulation of host immunity. We have previously shown that T-cell immunoglobulin and mucin domain protein-3 (Tim-3) is up-regulated on monocyte/macrophages (M/Mφ) during chronic HCV infection; little is known, however, about the transcription factor that controls its expression in these cells. In this study, we investigated the role of transcription factor, T-box expressed in T cells (T-bet), in Tim-3 expression in M/Mφ in the setting of HCV infection. We demonstrate that T-bet is constitutively expressed in resting CD14+ M/Mφ in the peripheral blood. M/Mφ from chronically HCV-infected individuals exhibit a significant increase in T-bet expression that positively correlates with an increased level of Tim-3 expression. Up-regulation of T-bet is also observed in CD14+ M/Mφ incubated with HCV+ Huh7.5 cells, as well as in primary M/Mφ or monocytic THP-1 cells exposed to HCV core protein in vitro, which is reversible by blocking HCV core/gC1qR interactions. Moreover, the HCV core-induced up-regulation of T-bet and Tim-3 expression in M/Mφ can be abrogated by incubating the cells with SP600125 – an inhibitor for the c-Jun N-terminal kinase (JNK) signalling pathway. Importantly, silencing T-bet gene expression decreases Tim-3 expression and enhances interleukin-12 secretion as well as signal transducer and activator of transcription 1 phosphorylation. These data suggest that T-bet, induced by the HCV core/gC1qR interaction, enhances Tim-3 expression via the JNK pathway, leading to dampened M/Mφ function during HCV infection. These findings reveal a novel mechanism for Tim-3 regulation via T-bet during HCV infection, providing new targets to combat this global epidemic viral disease.

No / Astrocyte reactivity is implicated in the neuronal loss underlying Alzheimer's disease. Curcumin has been shown to reduce astrocyte reactivity, though the exact pathways underlying these effects are incompletely understood. Here we investigated the role of the small ubiquitin-like modifier (SUMO) conjugation in mediating this effect of curcumin. In beta-amyloid (Aβ)-treated astrocytes, morphological changes and increased glial fibrillary acidic protein (GFAP) confirmed reactivity, which was accompanied by c-jun N-terminal kinase activation. Moreover, the levels of SUMO-1 conjugated proteins, as well as the conjugating enzyme, Ubc9, were decreased, with concomitant treatment with curcumin preventing these effects. Increasing SUMOylation in astrocytes, by over-expression of constitutively active SUMO-1, but not its inactive mutant, abrogated Aβ-induced increase in GFAP, suggesting astrocytes require SUMO-1 conjugation to remain non-reactive.

Prostate cancer is one of the leading causes of cancer-related deaths in men worldwide, with 10,000 new cases/year diagnosed in Sweden. In this context, there is an urgent need to identify new biomarkers to detect prostate cancer at an initial stage for earlier treatment intervention. Although how prostate cancer develops has not been fully established, the male sex hormone testosterone is a known prerequisite for prostate cancer development. High levels of transforming growth factor-β (TGFβ) are prognostically unfavorable in prostate cancer patients. TGFβ is a multifunctional cytokine that regulates a broad range of cellular responses. TGFβ signals through either the canonical Smad or the non-Smad signaling cascade. Cancerous cells develop different strategies to evade defense mechanisms and metastasize to different parts of the body. This thesis unveils one such novel mechanism related to TGFβ signaling. The first two articles provide evidence that TGFβ receptor type I (TβRI) is ubiquitinated by tumor necrosis factor receptor-associated factor 6 (TRAF6) and is cleaved at the ectodomain region by tumor necrosis factor alpha converting enzyme (TACE) in a protein kinase C zeta type-dependent manner. After TβRI is shed from the ectodomain, it undergoes a second cleavage by presenilin 1 (PS1), a γ-secretase catalytic subunit, which liberates the TβRI intracellular domain (TβRI-ICD) from the cell membrane. TRAF6 promotes TGFβ-dependent Lys63-linked polyubiquitination and recruitment of PS1 to the TβRI complex, and facilitates the cleavage of TβRI by PS1 to generate a TβRI-ICD. The TβRI-ICD then translocates to the nucleus, where it binds with the transcriptional co-activator p300 and regulates the transcription of pro-invasive target genes such as Snail1. Moreover, the nuclear translocated TβRI-ICD cooperates with the Notch intracellular domain (NICD), a core component in the Notch signaling pathway, to drive the expression of invasive genes. Interestingly, treatment with g-secretase inhibitors was able to inhibit cleavage of TβRI and inhibit the TGFβ-induced oncogenic pathway in an in vivo prostate cancer xenograft model. In the third article, we identified that Lysine 178 is the acceptor lysine in TβRI that is ubiquitinated by TRAF6. The TβRI K178R mutant was neither ubiquitinated nor translocated to the nucleus, and prevented transcriptional regulation of invasive genes in a dominant negative manner. In the fourth article, we show that TGFβ utilizes the E3-ligase TRAF6 and the p38 mitogen-activated protein kinase to phosphorylate c-Jun. In turn, the phosphorylated c-Jun activates p21 and Snail1 in a non-canonical Smad-independent pathway, and thereby promotes invasion in cancerous cells. In summary, we elucidate a new mechanism of TGFβ-induced oncogenic signal transduction in cancer cells in which TRAF6 plays a fundamental role. This opens a new avenue in the field of TGFβ signaling.

[Truncated abstract] Reactive oxygen species (ROS) have been implicated to play a major role in many pathological conditions including heart attack and stroke. Their ability to modulate the extracellular signal-regulated protein kinase (ERK) and c-Jun Nterminal kinase (JNK) signalling pathways, thereby influencing cellular response has been well-documented. Recent studies implicate a central role for mitochondria in ERK and JNK activation by ROS although the mechanisms remained unresolved. Using Jurkat T-lymphocyte as a cell model, this study demonstrated increased mitochondrial ROS production as a result of decreased mitochondrial complex activities mediated by hydrogen peroxide treatment. This is the first study to show that mitochondria are not essential for activating ERKs, however damaged mitochondria producing ROS can be expected to cause sustained ERK activation . . . This study revealed that JNK and its upstream kinases MKK4, MKK7 and ASK1 are associated with the mitochondria. Furthermore, findings from this study imply that JNK resides in the mitochondrial matrix. This study is the first to demonstrate that mitochondrial JNK can be activated in a cell-free environment by signals originating from the mitochondria. Experimental work using isolated mitochondria demonstrated that mitochondrial JNK can be activated by ROS generated from the mitochondria themselves. Flavin-containing proteins appear to be the main sources of mitochondrial-ROS which signal through redoxsensitive proteins to activate mitochondrial JNK.

The c-Jun NH2-terminal kinases (JNK) are evolutionarily conserved serine/threonine protein kinases that are activated by proinflammatory cytokines, environmental stress, and genotoxic agents. These kinases play key regulatory roles within a cell by coordinating signals from the cell surface to nuclear transcription factors. JNK phosphorylates the amino terminal domain of all three Jun transcription factors (JunB, c-Jun and JunD) all members of the AP-1 family. The activated transcription factors modulate gene expression to generate appropriate biological responses, including cell migration, proliferation, differentiation and cell death. The role of the JNK signaling pathway in cell death/apoptosis is controversial, both pro-apoptotic and pro-survival roles have been attributed to JNK. The mechanism that enables the JNK signaling pathway to mediate both apoptosis and survival is unclear. The aim of this study is to examine the role of TNF-stimulated JNK activation on cell survival. The proinflammatory cytokine TNF, is known to activate JNK and induce apoptosis. To test whether the JNK signaling pathway contributes to TNF-induced apoptosis, the response of wild type and Jnk1-/- Jnk2-/- (JNK deficient fibroblasts) fibroblasts to TNF was examined. JNK deficient fibroblasts are more sensitive to TNF-induced apoptosis than wild-type fibroblasts. The TNF-sensitivity cannot be attributed to altered expression of TNF receptors or defects in the NF-кB or AKT pathways, known anti-apoptotic signal transduction pathways. (In fact, TNF stimulated NF-кB activation provides a major mechanism to account for survival in both wild-type and JNK deficient cells.) However this increased TNF-sensitivity can be attributed to JNK deficiency. Apoptosis is suppressed in JNK deficient cells when transduced with JNK1 retrovirus. These data implicate the JNK signaling pathway in cell survival. The AP-1 family of transcription factors is a target of the JNK signal transduction pathway. In addition JNK is required for the normal expression of the AP-1 family member, JunD. Previous studies have indicated that JunD can mediate survival. Interestingly, JNK deficient and JunD null cells display similar phenotypes: premature senescence and increased sensitivity to TNF induced apoptosis. In fact, the TNF-sensitivity is also suppressed in JNK deficient fibroblasts transduced with JunD retrovirus. Although JunD can replace the survival signaling role of JNK, phosphorylation of JunD is essential to inhibit TNF induced apoptosis. JNK deficient cells transduced with phosphomutant JunD retrovirus maintain TNF-sensitivity. Activated transcription factors modulate gene expression. It is most likely that JunD functions by regulating the expression of key molecules that act to inhibit TNF-stimulated apoptosis. Microarray analysis comparing wild-type with JNK deficient fibroblasts revealed that the expression of the survival gene, cIAP-2, was induced by TNF in only wild-type fibroblasts. Furthermore, protein expression of cIAP-2 was induced by TNF in only wild-type fibroblasts. Analysis of the cIAP-2 promoter revealed two critical NF-кB binding sites and one AP-1 binding site. Luciferase reporter assays indicated key roles for both NF-кB and the AP-1 component, JunD in TNF-induced cIAP-2 gene expression. These experiments establish that the JNK/JunD pathway collaborates with NF-кB pathway to increase the expression of the anti-apoptotic protein cIAP-2 in TNF treated cells. Without this collaboration, the JNK pathway mediates apoptosis. The integration of JNK signaling with other signaling pathways represents a mechanism to account for the dual ability of the JNK pathway to mediate either survival or apoptosis. The dynamic coordination of signals within and between pathways is critical. The future challenge will be to fit the details of individual signaling pathways into the context of signaling networks.